Home | Welcome to Contract Pharma   
Last Updated Friday, May 24 2013
Print RSS Feed

Breaking News

Related Searches: Industry News •
Invitrogen To Acquire Applied Biosystems

June 13, 2008
Invitrogen Corp. has agreed to pay $6.4 billion in cash to acquire Applera's Applied Biosystems (AB) Group. AB develops DNA analysis devices for sequencing human genes. Earlier this year, the company announced it had sequenced an entire human genome…  Read More »
Parexel Makes Bid To Acquire ClinPhone

June 13, 2008
Parexel International has reached an agreement to acquire ClinPhone, a clinical technology organization headquartered in Nottingham, UK. The acquisition is based on the offer price of approximately $182 million.     Josef von Ricke…  Read More »
GSK To Cut R&D Staff

June 13, 2008
GlaxoSmithKline plans to cut 350 jobs, or 2% of its research staff, as part of an ongoing restructuring plan aimed at increasing productivity, according to a company statement.     "We continue to reshape our R&D operations…  Read More »
Almac Group Launches Oncology Division

June 12, 2008
Almac Group has created a separate division called Almac Discovery, focussed exclusively on the discovery and development of novel approaches to the treatment of cancer and associated conditions, with the goal of developing a biomarker or diagnostic…  Read More »
AMRI Earns Second BMS Milestone

June 12, 2008
AMRI will receive a $4 million milestone payment from Bristol-Myers Squibb following BMS's submission of a Clinical Trial Application (CTA) to the Health Products and Food Branch (HPFB), Health Canada for approval to initiate Phase I studies on an AM…  Read More »
Ricerca Biosciences

June 12, 2008
Sylvain Mandeville, Ph.D. has been named director of bioanalytical services, Ricerca Biosciences, LLC.  Dr. Mandeville will be responsible for all bioanalytical services and will be based in Concord, OH.     Dr. Mandeville has…  Read More »
Daiichi Sankyo To Buy Control of Ranbaxy

June 11, 2008
Daiichi Sankyo Co. plans to purchase a controlling stake in Ranbaxy Laboratories Ltd. for approximately $4.6 billion, acquiring 50.1% of the company, according to a company statement. Ranbaxy's chief executive officer, Malvinder Singh, will retain hi…  Read More »
Patheon Expands PR Facility

June 11, 2008
Patheon, Inc. is expanding its Manati, PR facility to add a dedicated high potency and controlled substance manufacturing area. The company will invest $2.8 million in a new 3,386-sq.-ft. area that will include three manufacturing suites, air lock co…  Read More »
WuXi, AZ Expand Collaboration

June 11, 2008
WuXi PharmaTech has signed a new three-year collaboration agreement with AstraZeneca, expanding a two-year, $14 million collaboration from April 2006 under which WuXi delivered more than 100,000 compounds ahead of schedule. Under the new agreement, W…  Read More »
Otsuka, UCB to Co-promote Drugs in Japan

June 10, 2008
UCB and Otsuka Pharmaceuticals Co. have signed collaboration agreements under which the two companies will co-promote the anti-epileptic drug, Keppra and Cimzia for the treatment of Crohn's Disease, in Japan. They will also co-develop and co-promote…  Read More »
IPS

June 10, 2008
Daniel G. Franklin has been appointed regional manager, compliance services, Integrated Project Services (IPS), based in Indiana. Also, Matthew Stefanowicz has been appointed regional manager, compliance services based in North Carolina.   …  Read More »
Cold Chain Technologies Expands

June 10, 2008
Cold Chain Technologies (CCT) has opened its new plant in Reno, NV and has expanded its plants in Massachusetts and Tennessee, doubling its Massachusetts thermal testing facility. Also, CCT has named Jeff Bernardi, Reno plant manager and Jamie Chaste…  Read More »
Amgen

June 9, 2008
Anna S. Richo has been appointed senior vice president, Worldwide Compliance, Amgen. Ms. Richo will head the organization responsible for the company’s corporate compliance and business ethics programs. She will report to Amgen chairman and chi…  Read More »
Takeda Diabetes Drug Gets Positive Results

June 9, 2008
Takeda Global R&D Center reported results from five Phase III studies of alogliptin as an oral treatment for type 2 diabetes, which has been shown to be a highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4). Alogliptin administered once…  Read More »
Exenatide Shows Benefits Over Byetta

June 9, 2008
Amylin Pharmaceuticals, Lilly and Alkermes announced results from a 30-week study comparing the efficacy of exenatide once weekly (a long-acting release formulation of exenatide) to Byetta (the injectable version of exenatide), in type 2 diabetes. Pa…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: